SERPINB1 and Angelman syndrome: Taken together, our findings advocate for the therapeutic potential of Lei-Dab7 or other KCNN2 blockers for FASD and possibly other neurodevelopmental diseases that similarly involve KCNN2 upregulation, such as Angelman syndrome.21